GlassScriptPhysician profile
Brittany M Harper
NPI 1154193084
$2,927.80
in general payments reported to CMS, 2019-2025
25 companies · $1,782 in 2025
The $1,782 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $245 · 2024: $900 · 2025: $1,782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,899 · Consulting Fee: $28.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,899.48 |
| Consulting Fee | $28.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $564.33 | 2024-2025 | Fasenra, Airsupra, Tezspire |
| Csl Behring | $449.34 | 2023-2025 | Haegarda, Hizentra, Andembry |
| Genzyme Corporation | $342.66 | 2023-2025 | |
| Ars Pharmaceuticals Operations, INC. | $229.92 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $218.52 | 2025 | |
| Glaxosmithkline, LLC. | $182.37 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genentech USA, INC. | $136.30 | 2023-2025 | Xolair |
| Alexion Pharmaceuticals, INC. | $122.80 | 2024 | Ultomiris |
| Tg Therapeutics, INC. | $121.18 | 2023 | |
| Biocryst US Sales Co., LLC | $72.95 | 2025 | Orladeyo |
| Pfizer INC. | $60.71 | 2024-2025 | |
| Cycle Pharmaceuticals INC | $56.73 | 2025 | Sajazir |
| Octapharma USA, INC. | $46.30 | 2024-2025 | Cutaquig |
| Amgen INC. | $39.75 | 2024 | Tezspire |
| Grifols USA, LLC | $38.46 | 2025 | Xembify |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ionis Pharmaceuticals, INC. | $36.76 | 2025 | Dawnzera |
| Regeneron Healthcare Solutions, INC. | $34.50 | 2025 | Dupixent |
| Optinose US, INC. | $30.88 | 2025 | |
| Tersera Therapeutics LLC | $29.73 | 2025 | Quzyttir |
| Adma Biomanufacturing LLC | $28.32 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.62 | 2024 | Cuvitru |
| Pharming Healthcare, INC. | $21.39 | 2025 | Ruconest |
| Galderma Laboratories, L.P. | $13.65 | 2025 | Nemluvio |
| Hikma Pharmaceuticals USA | $13.42 | 2024 | Ryaltris |
| Phadia US INC. | $13.21 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Harper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.